nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—Goserelin—prostate cancer	0.405	1	CrCtD
Degarelix—GNRHR—Goserelin—prostate cancer	0.265	1	CbGbCtD
Degarelix—Cetrorelix—Goserelin—prostate cancer	0.0788	0.315	CrCrCtD
Degarelix—Ceruletide—Goserelin—prostate cancer	0.0681	0.272	CrCrCtD
Degarelix—Nafarelin—Goserelin—prostate cancer	0.0541	0.216	CrCrCtD
Degarelix—Gonadorelin—Goserelin—prostate cancer	0.0493	0.197	CrCrCtD
Degarelix—GNRHR—Hormone ligand-binding receptors—GNRH1—prostate cancer	0.00149	0.132	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—GRPR—prostate cancer	0.000482	0.0429	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—GRPR—prostate cancer	0.000409	0.0363	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—MC2R—prostate cancer	0.000396	0.0352	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GRPR—prostate cancer	0.00023	0.0204	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRPR—prostate cancer	0.000205	0.0183	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—RLN2—prostate cancer	0.000173	0.0154	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRPR—prostate cancer	0.000152	0.0135	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GNRH1—prostate cancer	0.000143	0.0127	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—ADRB2—prostate cancer	0.000142	0.0126	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—LPAR1—prostate cancer	0.000138	0.0123	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GRP—prostate cancer	0.000138	0.0123	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—PLCB2—prostate cancer	0.000137	0.0122	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—RLN2—prostate cancer	0.000132	0.0117	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—prostate cancer	0.000128	0.0114	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—MC2R—prostate cancer	0.000125	0.0111	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GNG5—prostate cancer	0.000124	0.0111	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—prostate cancer	0.000124	0.011	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—prostate cancer	0.000124	0.011	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB2—prostate cancer	0.000123	0.0109	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GRPR—prostate cancer	0.000116	0.0103	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—PENK—prostate cancer	0.000111	0.00989	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG5—prostate cancer	0.000111	0.00988	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—ANXA1—prostate cancer	0.000102	0.00905	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—WNT4—prostate cancer	9.97e-05	0.00886	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—OR51E2—prostate cancer	9.81e-05	0.00872	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—MC2R—prostate cancer	9.52e-05	0.00845	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—GNRH1—prostate cancer	9.47e-05	0.00841	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—prostate cancer	9.17e-05	0.00815	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRP—prostate cancer	9.17e-05	0.00815	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—prostate cancer	9.11e-05	0.0081	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—OR51E2—prostate cancer	8.91e-05	0.00792	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	8.9e-05	0.00791	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—PRKCQ—prostate cancer	8.5e-05	0.00755	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PENK—prostate cancer	8.48e-05	0.00753	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RGS17—prostate cancer	8.34e-05	0.00741	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	7.61e-05	0.00676	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RGS17—prostate cancer	7.58e-05	0.00673	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—ITPR1—prostate cancer	7.56e-05	0.00672	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RLN2—prostate cancer	7.44e-05	0.00661	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GNRH1—prostate cancer	7.21e-05	0.00641	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GRP—prostate cancer	6.98e-05	0.0062	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—LPAR1—prostate cancer	6.98e-05	0.0062	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PLXNB1—prostate cancer	6.8e-05	0.00604	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CX3CL1—prostate cancer	6.78e-05	0.00602	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	6.76e-05	0.00601	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RLN2—prostate cancer	6.75e-05	0.006	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	6.75e-05	0.00599	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GRPR—prostate cancer	6.55e-05	0.00582	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GNG5—prostate cancer	6.27e-05	0.00557	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PLXNB1—prostate cancer	6.18e-05	0.00549	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	6.17e-05	0.00548	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GRPR—prostate cancer	5.95e-05	0.00528	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PTHLH—prostate cancer	5.47e-05	0.00486	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—MC2R—prostate cancer	5.38e-05	0.00478	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	5.29e-05	0.0047	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—OR51E2—prostate cancer	5.26e-05	0.00468	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—ANXA1—prostate cancer	5.14e-05	0.00456	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—WNT4—prostate cancer	5.12e-05	0.00455	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MC2R—prostate cancer	4.88e-05	0.00434	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BMPR1B—prostate cancer	4.82e-05	0.00428	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CALCA—prostate cancer	4.81e-05	0.00427	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PENK—prostate cancer	4.79e-05	0.00426	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL12—prostate cancer	4.7e-05	0.00418	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RGS17—prostate cancer	4.48e-05	0.00398	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PENK—prostate cancer	4.35e-05	0.00387	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	4.15e-05	0.00369	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—VIP—prostate cancer	4.08e-05	0.00362	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GNRH1—prostate cancer	4.08e-05	0.00362	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—ADRB2—prostate cancer	4.03e-05	0.00358	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RLN2—prostate cancer	3.99e-05	0.00354	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—LPAR1—prostate cancer	3.95e-05	0.00351	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GRP—prostate cancer	3.95e-05	0.00351	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PLCB2—prostate cancer	3.91e-05	0.00347	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CTBP2—prostate cancer	3.81e-05	0.00338	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HSD17B1—prostate cancer	3.81e-05	0.00338	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	3.78e-05	0.00336	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PDE4D—prostate cancer	3.73e-05	0.00331	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GNRH1—prostate cancer	3.7e-05	0.00329	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—VIP—prostate cancer	3.7e-05	0.00329	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PLXNB1—prostate cancer	3.65e-05	0.00324	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GRP—prostate cancer	3.58e-05	0.00318	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—LPAR1—prostate cancer	3.58e-05	0.00318	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PLCB2—prostate cancer	3.55e-05	0.00315	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GNG5—prostate cancer	3.55e-05	0.00315	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GRPR—prostate cancer	3.51e-05	0.00312	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CX3CL1—prostate cancer	3.48e-05	0.00309	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL17RD—prostate cancer	3.39e-05	0.00301	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PDE4D—prostate cancer	3.38e-05	0.00301	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GNG5—prostate cancer	3.22e-05	0.00286	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTHLH—prostate cancer	3.09e-05	0.00274	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JUP—prostate cancer	3.02e-05	0.00269	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—WNT4—prostate cancer	3.02e-05	0.00269	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ANXA1—prostate cancer	2.9e-05	0.00258	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RALBP1—prostate cancer	2.88e-05	0.00256	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MC2R—prostate cancer	2.88e-05	0.00256	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTHLH—prostate cancer	2.8e-05	0.00249	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PRKACB—prostate cancer	2.74e-05	0.00244	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CALCA—prostate cancer	2.72e-05	0.00242	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PPP3CA—prostate cancer	2.68e-05	0.00238	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL12—prostate cancer	2.66e-05	0.00236	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ANXA1—prostate cancer	2.64e-05	0.00234	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PENK—prostate cancer	2.57e-05	0.00228	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	2.56e-05	0.00227	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	2.52e-05	0.00224	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CALCA—prostate cancer	2.47e-05	0.00219	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GHR—prostate cancer	2.45e-05	0.00218	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3CA—prostate cancer	2.45e-05	0.00218	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PRKCQ—prostate cancer	2.42e-05	0.00215	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL12—prostate cancer	2.41e-05	0.00214	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	2.38e-05	0.00212	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NRP1—prostate cancer	2.35e-05	0.00209	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ADRB2—prostate cancer	2.28e-05	0.00202	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—VAV3—prostate cancer	2.22e-05	0.00197	CbGpPWpGaD
Degarelix—Malnutrition—Prednisone—prostate cancer	2.21e-05	0.000324	CcSEcCtD
Degarelix—Erythema—Prednisone—prostate cancer	2.21e-05	0.000324	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PRKCQ—prostate cancer	2.2e-05	0.00196	CbGpPWpGaD
Degarelix—Palpitations—Capecitabine—prostate cancer	2.19e-05	0.000321	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	2.19e-05	0.00195	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VIP—prostate cancer	2.19e-05	0.00194	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GNRH1—prostate cancer	2.19e-05	0.00194	CbGpPWpGaD
Degarelix—Decreased appetite—Etoposide—prostate cancer	2.19e-05	0.00032	CcSEcCtD
Degarelix—Arthralgia—Docetaxel—prostate cancer	2.18e-05	0.00032	CcSEcCtD
Degarelix—Renal failure—Epirubicin—prostate cancer	2.17e-05	0.000318	CcSEcCtD
Degarelix—Gastrointestinal disorder—Etoposide—prostate cancer	2.17e-05	0.000318	CcSEcCtD
Degarelix—Asthenia—Mitoxantrone—prostate cancer	2.17e-05	0.000318	CcSEcCtD
Degarelix—Fatigue—Etoposide—prostate cancer	2.17e-05	0.000318	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	2.16e-05	0.000317	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—ITPR1—prostate cancer	2.16e-05	0.00191	CbGpPWpGaD
Degarelix—Pain—Etoposide—prostate cancer	2.15e-05	0.000315	CcSEcCtD
Degarelix—Constipation—Etoposide—prostate cancer	2.15e-05	0.000315	CcSEcCtD
Degarelix—Urinary tract infection—Epirubicin—prostate cancer	2.15e-05	0.000315	CcSEcCtD
Degarelix—Dizziness—Estradiol—prostate cancer	2.15e-05	0.000314	CcSEcCtD
Degarelix—Dysuria—Doxorubicin—prostate cancer	2.14e-05	0.000314	CcSEcCtD
Degarelix—Hypertension—Capecitabine—prostate cancer	2.14e-05	0.000314	CcSEcCtD
Degarelix—Dry mouth—Docetaxel—prostate cancer	2.13e-05	0.000313	CcSEcCtD
Degarelix—Pollakiuria—Doxorubicin—prostate cancer	2.12e-05	0.000311	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GRP—prostate cancer	2.12e-05	0.00188	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LPAR1—prostate cancer	2.12e-05	0.00188	CbGpPWpGaD
Degarelix—Arthralgia—Capecitabine—prostate cancer	2.11e-05	0.000309	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	2.1e-05	0.000307	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PLCB2—prostate cancer	2.1e-05	0.00186	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LRP2—prostate cancer	2.1e-05	0.00186	CbGpPWpGaD
Degarelix—Hepatobiliary disease—Epirubicin—prostate cancer	2.09e-05	0.000306	CcSEcCtD
Degarelix—Anaphylactic shock—Docetaxel—prostate cancer	2.09e-05	0.000306	CcSEcCtD
Degarelix—Weight increased—Doxorubicin—prostate cancer	2.09e-05	0.000306	CcSEcCtD
Degarelix—Discomfort—Capecitabine—prostate cancer	2.09e-05	0.000306	CcSEcCtD
Degarelix—Vision blurred—Prednisone—prostate cancer	2.08e-05	0.000305	CcSEcCtD
Degarelix—Weight decreased—Doxorubicin—prostate cancer	2.07e-05	0.000304	CcSEcCtD
Degarelix—Feeling abnormal—Etoposide—prostate cancer	2.07e-05	0.000304	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—ADRB2—prostate cancer	2.07e-05	0.00184	CbGpPWpGaD
Degarelix—Hyperglycaemia—Doxorubicin—prostate cancer	2.07e-05	0.000303	CcSEcCtD
Degarelix—Diarrhoea—Mitoxantrone—prostate cancer	2.07e-05	0.000303	CcSEcCtD
Degarelix—Dry mouth—Capecitabine—prostate cancer	2.06e-05	0.000303	CcSEcCtD
Degarelix—Vomiting—Estradiol—prostate cancer	2.06e-05	0.000302	CcSEcCtD
Degarelix—Gastrointestinal pain—Etoposide—prostate cancer	2.06e-05	0.000301	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—P4HB—prostate cancer	2.06e-05	0.00183	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CX3CL1—prostate cancer	2.06e-05	0.00183	CbGpPWpGaD
Degarelix—Nervous system disorder—Docetaxel—prostate cancer	2.05e-05	0.0003	CcSEcCtD
Degarelix—Ill-defined disorder—Prednisone—prostate cancer	2.05e-05	0.0003	CcSEcCtD
Degarelix—Rash—Estradiol—prostate cancer	2.05e-05	0.0003	CcSEcCtD
Degarelix—Dermatitis—Estradiol—prostate cancer	2.04e-05	0.0003	CcSEcCtD
Degarelix—Anaemia—Prednisone—prostate cancer	2.04e-05	0.000299	CcSEcCtD
Degarelix—Headache—Estradiol—prostate cancer	2.03e-05	0.000298	CcSEcCtD
Degarelix—Skin disorder—Docetaxel—prostate cancer	2.03e-05	0.000298	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—VAV3—prostate cancer	2.02e-05	0.00179	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HIST1H2BG—prostate cancer	2.02e-05	0.00179	CbGpPWpGaD
Degarelix—Renal failure—Doxorubicin—prostate cancer	2.01e-05	0.000295	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GRB7—prostate cancer	2e-05	0.00178	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDE4D—prostate cancer	2e-05	0.00178	CbGpPWpGaD
Degarelix—Urticaria—Etoposide—prostate cancer	2e-05	0.000293	CcSEcCtD
Degarelix—Malaise—Prednisone—prostate cancer	1.99e-05	0.000292	CcSEcCtD
Degarelix—Abdominal pain—Etoposide—prostate cancer	1.99e-05	0.000291	CcSEcCtD
Degarelix—Body temperature increased—Etoposide—prostate cancer	1.99e-05	0.000291	CcSEcCtD
Degarelix—Urinary tract infection—Doxorubicin—prostate cancer	1.99e-05	0.000291	CcSEcCtD
Degarelix—Nervous system disorder—Capecitabine—prostate cancer	1.98e-05	0.000291	CcSEcCtD
Degarelix—Hypoaesthesia—Epirubicin—prostate cancer	1.97e-05	0.000289	CcSEcCtD
Degarelix—Skin disorder—Capecitabine—prostate cancer	1.97e-05	0.000288	CcSEcCtD
Degarelix—Urinary tract disorder—Epirubicin—prostate cancer	1.96e-05	0.000287	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—ITPR1—prostate cancer	1.96e-05	0.00174	CbGpPWpGaD
Degarelix—Hyperhidrosis—Capecitabine—prostate cancer	1.96e-05	0.000287	CcSEcCtD
Degarelix—Oedema peripheral—Epirubicin—prostate cancer	1.95e-05	0.000286	CcSEcCtD
Degarelix—Hypotension—Docetaxel—prostate cancer	1.95e-05	0.000286	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HIST1H4H—prostate cancer	1.95e-05	0.00173	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL8—prostate cancer	1.95e-05	0.00173	CbGpPWpGaD
Degarelix—Urethral disorder—Epirubicin—prostate cancer	1.94e-05	0.000285	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	1.94e-05	0.00172	CbGpPWpGaD
Degarelix—Hepatobiliary disease—Doxorubicin—prostate cancer	1.93e-05	0.000283	CcSEcCtD
Degarelix—Nausea—Estradiol—prostate cancer	1.93e-05	0.000282	CcSEcCtD
Degarelix—Vomiting—Mitoxantrone—prostate cancer	1.92e-05	0.000282	CcSEcCtD
Degarelix—Hypertension—Prednisone—prostate cancer	1.91e-05	0.000279	CcSEcCtD
Degarelix—Rash—Mitoxantrone—prostate cancer	1.91e-05	0.000279	CcSEcCtD
Degarelix—Dermatitis—Mitoxantrone—prostate cancer	1.9e-05	0.000279	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Docetaxel—prostate cancer	1.9e-05	0.000279	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GNG5—prostate cancer	1.9e-05	0.00169	CbGpPWpGaD
Degarelix—Headache—Mitoxantrone—prostate cancer	1.89e-05	0.000278	CcSEcCtD
Degarelix—Hypotension—Capecitabine—prostate cancer	1.89e-05	0.000277	CcSEcCtD
Degarelix—Insomnia—Docetaxel—prostate cancer	1.89e-05	0.000277	CcSEcCtD
Degarelix—Arthralgia—Prednisone—prostate cancer	1.88e-05	0.000276	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	1.87e-05	0.000274	CcSEcCtD
Degarelix—Dyspnoea—Docetaxel—prostate cancer	1.86e-05	0.000273	CcSEcCtD
Degarelix—Discomfort—Prednisone—prostate cancer	1.86e-05	0.000272	CcSEcCtD
Degarelix—Eye disorder—Epirubicin—prostate cancer	1.85e-05	0.000272	CcSEcCtD
Degarelix—Hypersensitivity—Etoposide—prostate cancer	1.85e-05	0.000272	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.84e-05	0.00027	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—prostate cancer	1.84e-05	0.00027	CcSEcCtD
Degarelix—Insomnia—Capecitabine—prostate cancer	1.83e-05	0.000268	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—prostate cancer	1.83e-05	0.000268	CcSEcCtD
Degarelix—Decreased appetite—Docetaxel—prostate cancer	1.82e-05	0.000266	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—prostate cancer	1.81e-05	0.000266	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—prostate cancer	1.81e-05	0.000265	CcSEcCtD
Degarelix—Gastrointestinal disorder—Docetaxel—prostate cancer	1.8e-05	0.000264	CcSEcCtD
Degarelix—Asthenia—Etoposide—prostate cancer	1.8e-05	0.000264	CcSEcCtD
Degarelix—Dyspnoea—Capecitabine—prostate cancer	1.8e-05	0.000264	CcSEcCtD
Degarelix—Anaphylactic shock—Prednisone—prostate cancer	1.8e-05	0.000264	CcSEcCtD
Degarelix—Fatigue—Docetaxel—prostate cancer	1.8e-05	0.000264	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—prostate cancer	1.8e-05	0.000264	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—prostate cancer	1.8e-05	0.000264	CcSEcCtD
Degarelix—Nausea—Mitoxantrone—prostate cancer	1.8e-05	0.000263	CcSEcCtD
Degarelix—Immune system disorder—Epirubicin—prostate cancer	1.79e-05	0.000263	CcSEcCtD
Degarelix—Mediastinal disorder—Epirubicin—prostate cancer	1.79e-05	0.000262	CcSEcCtD
Degarelix—Constipation—Docetaxel—prostate cancer	1.79e-05	0.000262	CcSEcCtD
Degarelix—Pain—Docetaxel—prostate cancer	1.79e-05	0.000262	CcSEcCtD
Degarelix—Chills—Epirubicin—prostate cancer	1.78e-05	0.000261	CcSEcCtD
Degarelix—Pruritus—Etoposide—prostate cancer	1.78e-05	0.000261	CcSEcCtD
Degarelix—Arrhythmia—Epirubicin—prostate cancer	1.77e-05	0.00026	CcSEcCtD
Degarelix—Nervous system disorder—Prednisone—prostate cancer	1.77e-05	0.000259	CcSEcCtD
Degarelix—Decreased appetite—Capecitabine—prostate cancer	1.76e-05	0.000258	CcSEcCtD
Degarelix—Alopecia—Epirubicin—prostate cancer	1.75e-05	0.000257	CcSEcCtD
Degarelix—Skin disorder—Prednisone—prostate cancer	1.75e-05	0.000257	CcSEcCtD
Degarelix—Gastrointestinal disorder—Capecitabine—prostate cancer	1.75e-05	0.000256	CcSEcCtD
Degarelix—Fatigue—Capecitabine—prostate cancer	1.74e-05	0.000256	CcSEcCtD
Degarelix—Hyperhidrosis—Prednisone—prostate cancer	1.74e-05	0.000255	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—prostate cancer	1.74e-05	0.000255	CcSEcCtD
Degarelix—Constipation—Capecitabine—prostate cancer	1.73e-05	0.000254	CcSEcCtD
Degarelix—Pain—Capecitabine—prostate cancer	1.73e-05	0.000254	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—prostate cancer	1.73e-05	0.000253	CcSEcCtD
Degarelix—Erythema—Epirubicin—prostate cancer	1.73e-05	0.000253	CcSEcCtD
Degarelix—Feeling abnormal—Docetaxel—prostate cancer	1.72e-05	0.000252	CcSEcCtD
Degarelix—Diarrhoea—Etoposide—prostate cancer	1.72e-05	0.000252	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—prostate cancer	1.72e-05	0.000251	CcSEcCtD
Degarelix—Gastrointestinal pain—Docetaxel—prostate cancer	1.71e-05	0.00025	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—prostate cancer	1.7e-05	0.00025	CcSEcCtD
Degarelix—Back pain—Epirubicin—prostate cancer	1.67e-05	0.000245	CcSEcCtD
Degarelix—Feeling abnormal—Capecitabine—prostate cancer	1.67e-05	0.000244	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—prostate cancer	1.67e-05	0.000244	CcSEcCtD
Degarelix—Dizziness—Etoposide—prostate cancer	1.66e-05	0.000244	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—prostate cancer	1.66e-05	0.000243	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—prostate cancer	1.66e-05	0.000243	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PTHLH—prostate cancer	1.66e-05	0.00147	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TGFBR1—prostate cancer	1.66e-05	0.00147	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Capecitabine—prostate cancer	1.65e-05	0.000243	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—prostate cancer	1.65e-05	0.000243	CcSEcCtD
Degarelix—Abdominal pain—Docetaxel—prostate cancer	1.65e-05	0.000242	CcSEcCtD
Degarelix—Body temperature increased—Docetaxel—prostate cancer	1.65e-05	0.000242	CcSEcCtD
Degarelix—Chills—Doxorubicin—prostate cancer	1.65e-05	0.000241	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Prednisone—prostate cancer	1.64e-05	0.000241	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—prostate cancer	1.64e-05	0.00024	CcSEcCtD
Degarelix—Insomnia—Prednisone—prostate cancer	1.63e-05	0.000239	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—AKR1C3—prostate cancer	1.63e-05	0.00145	CbGpPWpGaD
Degarelix—Vision blurred—Epirubicin—prostate cancer	1.63e-05	0.000239	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—prostate cancer	1.62e-05	0.000238	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PRKACB—prostate cancer	1.62e-05	0.00144	CbGpPWpGaD
Degarelix—Mental disorder—Doxorubicin—prostate cancer	1.61e-05	0.000236	CcSEcCtD
Degarelix—Urticaria—Capecitabine—prostate cancer	1.61e-05	0.000236	CcSEcCtD
Degarelix—Ill-defined disorder—Epirubicin—prostate cancer	1.6e-05	0.000235	CcSEcCtD
Degarelix—Body temperature increased—Capecitabine—prostate cancer	1.6e-05	0.000234	CcSEcCtD
Degarelix—Abdominal pain—Capecitabine—prostate cancer	1.6e-05	0.000234	CcSEcCtD
Degarelix—Vomiting—Etoposide—prostate cancer	1.6e-05	0.000234	CcSEcCtD
Degarelix—Erythema—Doxorubicin—prostate cancer	1.6e-05	0.000234	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—prostate cancer	1.6e-05	0.000234	CcSEcCtD
Degarelix—Anaemia—Epirubicin—prostate cancer	1.6e-05	0.000234	CcSEcCtD
Degarelix—Rash—Etoposide—prostate cancer	1.59e-05	0.000232	CcSEcCtD
Degarelix—Dermatitis—Etoposide—prostate cancer	1.58e-05	0.000232	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PPP3CA—prostate cancer	1.58e-05	0.0014	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—THBS1—prostate cancer	1.58e-05	0.0014	CbGpPWpGaD
Degarelix—Headache—Etoposide—prostate cancer	1.58e-05	0.000231	CcSEcCtD
Degarelix—Decreased appetite—Prednisone—prostate cancer	1.57e-05	0.00023	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ANXA1—prostate cancer	1.56e-05	0.00138	CbGpPWpGaD
Degarelix—Malaise—Epirubicin—prostate cancer	1.56e-05	0.000228	CcSEcCtD
Degarelix—Fatigue—Prednisone—prostate cancer	1.55e-05	0.000228	CcSEcCtD
Degarelix—Back pain—Doxorubicin—prostate cancer	1.55e-05	0.000227	CcSEcCtD
Degarelix—Constipation—Prednisone—prostate cancer	1.54e-05	0.000226	CcSEcCtD
Degarelix—Hypersensitivity—Docetaxel—prostate cancer	1.54e-05	0.000226	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—prostate cancer	1.54e-05	0.000225	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PRKCZ—prostate cancer	1.53e-05	0.00136	CbGpPWpGaD
Degarelix—Palpitations—Epirubicin—prostate cancer	1.53e-05	0.000224	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—prostate cancer	1.51e-05	0.000221	CcSEcCtD
Degarelix—Asthenia—Docetaxel—prostate cancer	1.5e-05	0.00022	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CG—prostate cancer	1.49e-05	0.00133	CbGpPWpGaD
Degarelix—Nausea—Etoposide—prostate cancer	1.49e-05	0.000219	CcSEcCtD
Degarelix—Hypertension—Epirubicin—prostate cancer	1.49e-05	0.000219	CcSEcCtD
Degarelix—Hypersensitivity—Capecitabine—prostate cancer	1.49e-05	0.000218	CcSEcCtD
Degarelix—Feeling abnormal—Prednisone—prostate cancer	1.49e-05	0.000218	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—prostate cancer	1.48e-05	0.000217	CcSEcCtD
Degarelix—Pruritus—Docetaxel—prostate cancer	1.48e-05	0.000217	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—prostate cancer	1.48e-05	0.000216	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGFR4—prostate cancer	1.48e-05	0.00131	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PARP1—prostate cancer	1.48e-05	0.00131	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Prednisone—prostate cancer	1.47e-05	0.000216	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—prostate cancer	1.47e-05	0.000216	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.46e-05	0.000214	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CALCA—prostate cancer	1.46e-05	0.0013	CbGpPWpGaD
Degarelix—Discomfort—Epirubicin—prostate cancer	1.45e-05	0.000213	CcSEcCtD
Degarelix—Asthenia—Capecitabine—prostate cancer	1.45e-05	0.000213	CcSEcCtD
Degarelix—Malaise—Doxorubicin—prostate cancer	1.44e-05	0.000211	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—prostate cancer	1.44e-05	0.000211	CcSEcCtD
Degarelix—Urticaria—Prednisone—prostate cancer	1.43e-05	0.00021	CcSEcCtD
Degarelix—Pruritus—Capecitabine—prostate cancer	1.43e-05	0.00021	CcSEcCtD
Degarelix—Diarrhoea—Docetaxel—prostate cancer	1.43e-05	0.00021	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CXCL12—prostate cancer	1.42e-05	0.00127	CbGpPWpGaD
Degarelix—Body temperature increased—Prednisone—prostate cancer	1.42e-05	0.000209	CcSEcCtD
Degarelix—Abdominal pain—Prednisone—prostate cancer	1.42e-05	0.000209	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—prostate cancer	1.41e-05	0.000207	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—prostate cancer	1.41e-05	0.000207	CcSEcCtD
Degarelix—Diarrhoea—Capecitabine—prostate cancer	1.38e-05	0.000203	CcSEcCtD
Degarelix—Nervous system disorder—Epirubicin—prostate cancer	1.38e-05	0.000203	CcSEcCtD
Degarelix—Dizziness—Docetaxel—prostate cancer	1.38e-05	0.000203	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—prostate cancer	1.38e-05	0.000202	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—prostate cancer	1.37e-05	0.000201	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—prostate cancer	1.36e-05	0.0002	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—prostate cancer	1.36e-05	0.000199	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CG—prostate cancer	1.36e-05	0.00121	CbGpPWpGaD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.35e-05	0.000198	CcSEcCtD
Degarelix—Discomfort—Doxorubicin—prostate cancer	1.34e-05	0.000197	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CASP9—prostate cancer	1.34e-05	0.00119	CbGpPWpGaD
Degarelix—Dizziness—Capecitabine—prostate cancer	1.34e-05	0.000196	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—prostate cancer	1.33e-05	0.000195	CcSEcCtD
Degarelix—Vomiting—Docetaxel—prostate cancer	1.33e-05	0.000195	CcSEcCtD
Degarelix—Hypersensitivity—Prednisone—prostate cancer	1.33e-05	0.000195	CcSEcCtD
Degarelix—Rash—Docetaxel—prostate cancer	1.32e-05	0.000193	CcSEcCtD
Degarelix—Hypotension—Epirubicin—prostate cancer	1.32e-05	0.000193	CcSEcCtD
Degarelix—Dermatitis—Docetaxel—prostate cancer	1.32e-05	0.000193	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CD—prostate cancer	1.31e-05	0.00117	CbGpPWpGaD
Degarelix—Headache—Docetaxel—prostate cancer	1.31e-05	0.000192	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—prostate cancer	1.3e-05	0.000191	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PRKCQ—prostate cancer	1.3e-05	0.00115	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NGFR—prostate cancer	1.3e-05	0.00115	CbGpPWpGaD
Degarelix—Asthenia—Prednisone—prostate cancer	1.29e-05	0.00019	CcSEcCtD
Degarelix—Vomiting—Capecitabine—prostate cancer	1.29e-05	0.000189	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—MAP3K7—prostate cancer	1.28e-05	0.00114	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.28e-05	0.000188	CcSEcCtD
Degarelix—Nervous system disorder—Doxorubicin—prostate cancer	1.28e-05	0.000187	CcSEcCtD
Degarelix—Rash—Capecitabine—prostate cancer	1.28e-05	0.000187	CcSEcCtD
Degarelix—Pruritus—Prednisone—prostate cancer	1.28e-05	0.000187	CcSEcCtD
Degarelix—Insomnia—Epirubicin—prostate cancer	1.27e-05	0.000187	CcSEcCtD
Degarelix—Dermatitis—Capecitabine—prostate cancer	1.27e-05	0.000187	CcSEcCtD
Degarelix—Headache—Capecitabine—prostate cancer	1.27e-05	0.000186	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—prostate cancer	1.27e-05	0.000186	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—prostate cancer	1.26e-05	0.000185	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—prostate cancer	1.26e-05	0.000184	CcSEcCtD
Degarelix—Nausea—Docetaxel—prostate cancer	1.24e-05	0.000182	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGF10—prostate cancer	1.24e-05	0.0011	CbGpPWpGaD
Degarelix—Diarrhoea—Prednisone—prostate cancer	1.23e-05	0.000181	CcSEcCtD
Degarelix—Decreased appetite—Epirubicin—prostate cancer	1.23e-05	0.00018	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ADRB2—prostate cancer	1.22e-05	0.00109	CbGpPWpGaD
Degarelix—Hypotension—Doxorubicin—prostate cancer	1.22e-05	0.000179	CcSEcCtD
Degarelix—Gastrointestinal disorder—Epirubicin—prostate cancer	1.22e-05	0.000178	CcSEcCtD
Degarelix—Fatigue—Epirubicin—prostate cancer	1.22e-05	0.000178	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—JAK2—prostate cancer	1.21e-05	0.00107	CbGpPWpGaD
Degarelix—Constipation—Epirubicin—prostate cancer	1.21e-05	0.000177	CcSEcCtD
Degarelix—Pain—Epirubicin—prostate cancer	1.21e-05	0.000177	CcSEcCtD
Degarelix—Nausea—Capecitabine—prostate cancer	1.2e-05	0.000176	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—MAP2K1—prostate cancer	1.2e-05	0.00107	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CD—prostate cancer	1.19e-05	0.00106	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VAV3—prostate cancer	1.19e-05	0.00106	CbGpPWpGaD
Degarelix—Dizziness—Prednisone—prostate cancer	1.19e-05	0.000175	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.19e-05	0.000174	CcSEcCtD
Degarelix—Insomnia—Doxorubicin—prostate cancer	1.18e-05	0.000173	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TGFBR2—prostate cancer	1.17e-05	0.00104	CbGpPWpGaD
Degarelix—Dyspnoea—Doxorubicin—prostate cancer	1.16e-05	0.00017	CcSEcCtD
Degarelix—Feeling abnormal—Epirubicin—prostate cancer	1.16e-05	0.00017	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ITPR1—prostate cancer	1.16e-05	0.00103	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Epirubicin—prostate cancer	1.15e-05	0.000169	CcSEcCtD
Degarelix—Vomiting—Prednisone—prostate cancer	1.15e-05	0.000168	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CB—prostate cancer	1.15e-05	0.00102	CbGpPWpGaD
Degarelix—Rash—Prednisone—prostate cancer	1.14e-05	0.000167	CcSEcCtD
Degarelix—Dermatitis—Prednisone—prostate cancer	1.14e-05	0.000166	CcSEcCtD
Degarelix—Decreased appetite—Doxorubicin—prostate cancer	1.13e-05	0.000166	CcSEcCtD
Degarelix—Headache—Prednisone—prostate cancer	1.13e-05	0.000165	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.13e-05	0.000165	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—prostate cancer	1.12e-05	0.000165	CcSEcCtD
Degarelix—Urticaria—Epirubicin—prostate cancer	1.12e-05	0.000164	CcSEcCtD
Degarelix—Constipation—Doxorubicin—prostate cancer	1.12e-05	0.000163	CcSEcCtD
Degarelix—Pain—Doxorubicin—prostate cancer	1.12e-05	0.000163	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—prostate cancer	1.11e-05	0.000163	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—prostate cancer	1.11e-05	0.000163	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—IGF1R—prostate cancer	1.11e-05	0.000982	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL8—prostate cancer	1.1e-05	0.000978	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—JAK2—prostate cancer	1.09e-05	0.000973	CbGpPWpGaD
Degarelix—Feeling abnormal—Doxorubicin—prostate cancer	1.07e-05	0.000158	CcSEcCtD
Degarelix—Nausea—Prednisone—prostate cancer	1.07e-05	0.000157	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—prostate cancer	1.07e-05	0.000156	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—LPL—prostate cancer	1.06e-05	0.000942	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL2—prostate cancer	1.05e-05	0.000934	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDGFRB—prostate cancer	1.05e-05	0.000933	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CB—prostate cancer	1.04e-05	0.000924	CbGpPWpGaD
Degarelix—Hypersensitivity—Epirubicin—prostate cancer	1.04e-05	0.000152	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—prostate cancer	1.04e-05	0.000152	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—prostate cancer	1.03e-05	0.000151	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—prostate cancer	1.03e-05	0.000151	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ITGB3—prostate cancer	1.02e-05	0.000909	CbGpPWpGaD
Degarelix—Asthenia—Epirubicin—prostate cancer	1.01e-05	0.000148	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CXCL8—prostate cancer	9.99e-06	0.000888	CbGpPWpGaD
Degarelix—Pruritus—Epirubicin—prostate cancer	9.97e-06	0.000146	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ERBB3—prostate cancer	9.93e-06	0.000882	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGFR2—prostate cancer	9.91e-06	0.000881	CbGpPWpGaD
Degarelix—Diarrhoea—Epirubicin—prostate cancer	9.64e-06	0.000141	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—prostate cancer	9.61e-06	0.000141	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—IL2—prostate cancer	9.55e-06	0.000848	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TERT—prostate cancer	9.52e-06	0.000845	CbGpPWpGaD
Degarelix—Asthenia—Doxorubicin—prostate cancer	9.36e-06	0.000137	CcSEcCtD
Degarelix—Dizziness—Epirubicin—prostate cancer	9.32e-06	0.000137	CcSEcCtD
Degarelix—Pruritus—Doxorubicin—prostate cancer	9.23e-06	0.000135	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HIF1A—prostate cancer	9.1e-06	0.000808	CbGpPWpGaD
Degarelix—Vomiting—Epirubicin—prostate cancer	8.96e-06	0.000131	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—prostate cancer	8.92e-06	0.000131	CcSEcCtD
Degarelix—Rash—Epirubicin—prostate cancer	8.89e-06	0.00013	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—LEP—prostate cancer	8.88e-06	0.000789	CbGpPWpGaD
Degarelix—Dermatitis—Epirubicin—prostate cancer	8.88e-06	0.00013	CcSEcCtD
Degarelix—Headache—Epirubicin—prostate cancer	8.83e-06	0.000129	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CAV1—prostate cancer	8.8e-06	0.000782	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KDR—prostate cancer	8.7e-06	0.000773	CbGpPWpGaD
Degarelix—Dizziness—Doxorubicin—prostate cancer	8.62e-06	0.000126	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ESR1—prostate cancer	8.48e-06	0.000753	CbGpPWpGaD
Degarelix—Nausea—Epirubicin—prostate cancer	8.37e-06	0.000123	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—prostate cancer	8.29e-06	0.000122	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—BAD—prostate cancer	8.28e-06	0.000735	CbGpPWpGaD
Degarelix—Rash—Doxorubicin—prostate cancer	8.22e-06	0.000121	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—prostate cancer	8.22e-06	0.00012	CcSEcCtD
Degarelix—Headache—Doxorubicin—prostate cancer	8.17e-06	0.00012	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—APC—prostate cancer	8.02e-06	0.000712	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CG—prostate cancer	8.02e-06	0.000712	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IRS1—prostate cancer	7.92e-06	0.000704	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGF—prostate cancer	7.92e-06	0.000704	CbGpPWpGaD
Degarelix—Nausea—Doxorubicin—prostate cancer	7.75e-06	0.000114	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GSK3B—prostate cancer	7.69e-06	0.000683	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—INS—prostate cancer	7.59e-06	0.000674	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CREBBP—prostate cancer	7.43e-06	0.00066	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IGF1—prostate cancer	7.34e-06	0.000652	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EGFR—prostate cancer	7.3e-06	0.000649	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAP2K1—prostate cancer	7.09e-06	0.00063	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CD—prostate cancer	7.05e-06	0.000626	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CA—prostate cancer	6.98e-06	0.00062	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SERPINE1—prostate cancer	6.97e-06	0.000619	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KRAS—prostate cancer	6.9e-06	0.000613	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGF2—prostate cancer	6.75e-06	0.0006	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOS3—prostate cancer	6.66e-06	0.000591	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JAK2—prostate cancer	6.47e-06	0.000575	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CA—prostate cancer	6.34e-06	0.000563	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MDM2—prostate cancer	6.31e-06	0.000561	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ERBB2—prostate cancer	6.23e-06	0.000553	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CB—prostate cancer	6.14e-06	0.000546	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL8—prostate cancer	5.9e-06	0.000524	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1B—prostate cancer	5.77e-06	0.000512	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—prostate cancer	5.7e-06	0.000507	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CASP3—prostate cancer	5.65e-06	0.000502	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL2—prostate cancer	5.64e-06	0.000501	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6—prostate cancer	5.61e-06	0.000499	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—prostate cancer	5.5e-06	0.000489	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CTNNB1—prostate cancer	5.45e-06	0.000484	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP9—prostate cancer	5.34e-06	0.000474	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1A—prostate cancer	5.32e-06	0.000473	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTEN—prostate cancer	5.31e-06	0.000472	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—prostate cancer	5.18e-06	0.00046	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EP300—prostate cancer	5.06e-06	0.00045	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SRC—prostate cancer	4.92e-06	0.000437	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—prostate cancer	4.79e-06	0.000426	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—prostate cancer	4.75e-06	0.000422	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYC—prostate cancer	4.41e-06	0.000392	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TGFB1—prostate cancer	4.4e-06	0.000391	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGFR—prostate cancer	4.31e-06	0.000383	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—prostate cancer	4.08e-06	0.000362	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CA—prostate cancer	3.74e-06	0.000333	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—prostate cancer	3.62e-06	0.000322	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6—prostate cancer	3.32e-06	0.000295	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—prostate cancer	3.06e-06	0.000272	CbGpPWpGaD
